Dermata Therapeutics (NASDAQ:DRMA) Raised to “Sell” at Wall Street Zen

Dermata Therapeutics (NASDAQ:DRMA) was upgraded by research analysts at Wall Street Zen to a “sell” rating in a research note issued on Saturday.

Separately, Weiss Ratings reaffirmed a “sell (e)” rating on shares of Dermata Therapeutics in a research report on Monday, December 29th. One equities research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Dermata Therapeutics currently has an average rating of “Hold” and an average price target of $10.00.

Dermata Therapeutics Stock Down 19.9%

Shares of NASDAQ DRMA opened at $2.25 on Friday. Dermata Therapeutics has a 12-month low of $1.58 and a 12-month high of $23.70. The firm’s 50-day simple moving average is $2.46 and its 200 day simple moving average is $4.12. The company has a market cap of $6.39 million, a price-to-earnings ratio of -0.29 and a beta of 0.54.

Dermata Therapeutics (NASDAQ:DRMA) last announced its quarterly earnings data on Friday, November 14th. The company reported ($1.65) earnings per share for the quarter, missing the consensus estimate of ($1.59) by ($0.06).

About Dermata Therapeutics

Dermata Therapeutics is a clinical-stage immunodermatology company dedicated to developing novel small-molecule therapies for inflammatory skin disorders. The company’s lead clinical candidate, DMVT-502, is being evaluated in atopic dermatitis, while DMVT-505 is in development for vitiligo. In addition to these programs, Dermata advances preclinical assets targeting other indications such as alopecia areata.

At the core of Dermata’s approach is a proprietary drug discovery platform that combines structure-based design, medicinal chemistry and innovative formulation techniques.